Neutricks LLC Acquire Worldwide Rights to Market Dietary Supplements for Companion Animals from Quincy Bioscience, Inc.

MADISON, Wis., March 11, 2015 /PRNewswire/ -- Neutricks LLC & Quincy Bioscience, Inc., announced today an exclusive worldwide licensing agreement to market Neutricks dietary supplements for aging dogs, cats and horses. Quincy Animal Health, LLC a subsidiary of Quincy Bioscience, Inc., currently markets Neutricks.

Michael J. Beaman, CEO of Quincy Bioscience, said: "We are very pleased that Neutricks will now be marketed worldwide exclusively by Neutricks LLC, which will be solely focused on building Neutricks into a global brand."

Mr. Paul W. Pendorf assumes the position of Neutricks LLC Board Chairman and CEO. Mr. Joseph F. Andolino, Esq. a Managing Partner of Neutricks LLC was named Vice Chairman and Mr. David Merrick, formerly General Manager of Quincy Animal Health, LLC was named President of the new entity.

Paul W. Pendorf, is a veteran of Pfizer and Pfizer International. He later served within the Pharma and Ag-Vet business areas of American Cyanamid International. Mr. Pendorf commented: " I have been involved for several years, working with Quincy Bioscience's unique fermentation based technology in both human and animal applications. When Quincy agreed to licensing their patented Animal Products Business, we jumped at the chance."

ABOUT QUINCY BIOSCIENCE
Headquartered in Madison, Wisconsin, Quincy Bioscience is a leading biotechnology company focused on the delivery, development and commercialization of novel technologies that address brain health and other age-related health challenges, including memory loss. The Company utilizes an innovative protein to manufacture its flagship product, Prevagen®, which is sold directly to consumers through direct response marketing campaigns and available at major drug store chains in the United States.

SOURCE Neutricks LLC; Quincy Bioscience, Inc.